Osiris Therapeutics, Inc.
Osiris Therapeutics, Inc., having developed the world’s first approved stem cell drug, Prochymal®, is the leading stem cell company. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets. Osiris‘ Biosurgery segment seeks to harness the ability of cells and novel constructs to promote the body's natural healing, with the goals of improving surgical outcomes and offering better treatment options for patients and physicians. Osiris currently markets and sells Grafix® and Ovation® for tissue repair. The Company’s Therapeutics segment is focused on developing biologic stem cell drug candidates from a readily available and non-controversial source - adult bone marrow. The Company‘s lead biologic drug candidate, Prochymal (remestemcel-L), is approved in Canada and New Zealand for the management of acute graft-versus-host disease (GvHD) in children and is available for adults and children in eight countries including the United States, under an Expanded Access Program. Prochymal is currently in Phase 3 trials for refractory Crohn’s disease and is also being evaluated in clinical trials for the treatment of myocardial infarction (heart attack) and type 1 diabetes. Osiris’ stem cell products have significant therapeutic potential because of their ability to regulate inflammation, promote tissue regeneration and prevent scar formation.
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient’s lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.
The goal of Myriad is to make a difference in patient’s lives and for the past twenty years, the Company’s strategy has been guided by this mission. To accomplish this, Myriad is focused on revolutionizing patient care through the development and marketing of transformative tests which address pressing clinical needs across multiple medical specialties.
Over the last twenty years, Myriad has invested heavily in the education of patients and health care providers on the role genes and their related proteins play in disease. Almost one million patients have already benefited from Myriad’s informative testing, which helps physicians better manage their health care.
Today, Myriad continues to build on this strong tradition. It is working to expand its reach by introducing newgenetic tests and molecular diagnostic tests for a number of diseases. The Company is also focused on extending our mission internationally, in an effort to broaden our geographic footprint and provide critical information to more patients and healthcare providers.